Grants and Contributions:
Title:
Development of new perfusion applications
Agreement Number:
1006748
Agreement Value:
$424,050.00
Agreement Date:
Jun 5, 2023 - Aug 31, 2024
Description:
Traferox will design, manufacture, and validate systems that can perform normothermic ex vivo perfusion of the liver and the heart. In normothermic ex vivo organ perfusion, solid organs are perfused with a solution containing red blood cells and maintained at body temperature. Normothermic ex vivo organ perfusion enables detailed functional assessment of the organ and assessment of their suitability for transplant. This project will create systems suitable for preclinical research.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Mississauga, Ontario, CA L5L 5Y7
Reference Number:
172-2023-2024-Q1-1006748
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
717995286
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 2 time(s). The total amended value is 44,000 dollars.
Amendment Date
Feb 20, 2024
Recipient's Legal Name:
Traferox Technologies Inc
Federal Riding Name:
Mississauga--Erin Mills
Federal Riding Number:
35060
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
339110
Amendments: